Market Overview

Bristol-Myers Up Big After Drug Study Stopped Early

Share:
Bristol-Myers Up Big After Drug Study Stopped Early

Bristol-Myers Squibb Co (NYSE: BMY) was more than 3 percent higher in early trading after the company announced that Phase III study of Opdivo was stopped early after the trial "met its endpoint," according to a press release from the company. Opdivo "demonstrated superior overall survival" in patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Opdivo received approval from the U.S. Food and Drug Administration as a monotherapy in two cancer indications. Bristol-Myers said that patients in the trial will have the opportunity to continue or start treatment with Opdivo.

Bristol-Myers was 2.7 percent higher at last trade of $65.40. The stock has gained 11 percent this year and 32 percent over the prior 52 weeks. The company is still below its all-time peak around $80 per share hit in 1999.

Posted-In: bristol-myers squibbBiotech News FDA Movers General Best of Benzinga

 

Related Articles (BMY)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com